Bora Pharmaceutical CDMO
Bora Pharmaceutical CDMO develops prescription and OTC products from late-phase clinical through to commercial manufacturing and packaging, focusing on complex oral solid dosage (tablet & capsules); liquids (solutions, suspensions, and nasal sprays); and semi-solids (cream & gels).
7333 Mississauga Road
Phone / ContactT: +1 866 674 2762
E: [email protected]
Bora Pharmaceutical CDMO is an international cGMP CDMO for prescription and OTC products from late-phase clinical through commercial manufacturing and packaging. It’s key areas of speciality are: complex oral solid dosage (tablet & capsules); liquids (solutions, suspensions, and nasal sprays); and semi-solids (cream & gels). The company can handle high potency compounds, solvents, flammables, and IR/SR/ER release profile products.
Its oral solid dosage form service offering includes immediate- and controlled/extended-release formulations, extrusion/spheronisation, beads, tray drying, solvent handling, film coating, and a fluidised coating system (Wurster).
It has three state-of-the-art CGMP manufacturing facilities in Taiwan and Canada for manufacturing, packaging, R&D, and analytical testing.
Bora Pharmaceutical CDMO is part of Taiwan-based Bora Pharmaceuticals Co Ltd, whose stock is traded on the Taiwan Stock Exchange (6472). Bora originated from Hoan Pharmaceuticals, which was founded in 1973 John W. Sheng. Bora was established in 2007 as an independent entity, focused on innovative drug development and high-quality CMO/CDMO production for International markets.